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Anemia is still the most common disease among the world population, and it affects 1.6 billion people worldwide.2 In various ages of life, it seems to be par-ticularly prevalent: childhood, females of childbear-
ing age, and old age. In most cases, these are anemias due to 
acquired causes, while cumulatively the hereditary causes make 
up about 7% of the total.
Among these, thalassemias and other hemoglobinopathies 
have acquired considerable importance in Europe in consider-
ation of the globalization and the arrival of immigrants from 
regions with a significant incidence. For these reasons, one of the 
problems of public health in many European countries is repre-
sented by these pathologies which require transfusion interven-
tions and management of chronic and acute pathologies.
One of both today’s and future goals of these pathology treat-
ments is represented by precision diagnostics, considering that it 
is no longer enough to identify the causative gene only, but the 
identification of the cohort of genes that significantly modify 
the phenotype is mandatory mainly for the outcome definition 
(Figure 1).
A particular emphasis is given to the search for new effective 
therapies in hereditary diseases. Among them were new stem cell 
transplantation techniques and new approaches such as gene 
therapy and genome editing, which allow to solve the problem 
of transplant rejection and the scarcity of donors.
The consequences of morbidity associated with chronic ane-
mia extend to loss of productivity from impaired work capac-
ity, cognitive impairment, increased susceptibility to infection, 
and in the elderly, a huge contribution to comorbidities, which 
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exerts a very substantial economic burden on healthcare sys-
tems.3 Nevertheless, anemia frequently goes unrecognized and 
untreated, causing high direct and indirect costs at both the indi-
vidual and national levels.
Healthcare services in these countries have to deal with 
increasingly culturally diverse populations. It is noteworthy 
that, due to the immigrant movements in Europe, there is a new 
epidemiology of acquired and inherited anemias.4 It is import-
ant for planning for health intervention to know exactly the 
distribution of the different form of anemia in each country. To 
carry out this, it appears mandatory to have European guide-
lines for diagnosis and establish a common and more sustain-
able therapeutic approach.
Moreover, clinical trials on new drugs and therapeutic proce-
dures could ameliorate the quality of patients affected with the 
diseases, mainly in the inherited form, and enhance the quality 
of their life and life expectancy.
Coordinated efforts should be made to develop strategies for 
prevention of acquired and inherited anemias in individuals at 
risk in Europe. Detailed epidemiological studies in all countries, 
especially western countries, are a prerequisite for the imple-
mentation of effective prevention programs.
For a correct diagnosis is mandatory to have a shared diag-
nostic flowchart for each of the main form of anemias. Thus, 
the development of new tools to reliably diagnose anemias is 
urgently needed and fits well with the needs of personalized 
medicine. We expect that the development of such a diagnostic 
tool will improve timely diagnosis throughout Europe, espe-
cially in those countries where it is difficult to gain access to 
“classical” diagnostic tests.
In the last 15 years, hematology research has made a big leap 
forward. The emergence of sophisticated genetic and molecular 
tools (ie, next-generation sequencing [NGS] technique) allowed 
spectacular progresses in our understanding of the structure and 
function of the blood cells in health and disease. Our general 
aim will be to solve several hematologic problems using these 
new approaches.5,6
Research on rare genetic iron-related diseases that are infor-
mative biological models may contribute to further under-
standing of iron metabolism. Their precise diagnosis might lead 
to avoid unnecessary and costly diagnostic tests and possibly 
harmful treatments.
New technologies for anemia and related 
disorders
Where we are now
Anemia, defined as a decreased amount of hemoglobin, can 
result from blood loss but also from decreased synthesis of hemo-
globin, decreased erythrocyte (RBC) production, or increased 
RBC destruction. The clinical cost and socio-economic impact 
of these disorders is tremendous. Anemia of inflammation (AI), 
chronic kidney disease (CKD), myelodysplastic syndromes 
(MDS), hemolytic anemias, and some forms of BM failure rep-
resent a growing and pressing medical and socioeconomic issue 
in Europe. Children affected by hemoglobinopathies require 
long-life transfusion for survival but, eventually, a considerable 
morbidity develops leading to a decreased lifespan.
Clinical management includes administration of anti-inflam-
matory molecules in AI, erythropoiesis-stimulating agent and 
iron in CKD, blood transfusion, administration of hematopoi-
etic growth factors, low-intensity chemotherapy, and BM trans-
plantation in MDS. Hemoglobinopathies represent the most 
frequent disorder worldwide, with at least 300,000 children 
born with these disorders every year. Clinical management has 
been focusing on supportive therapy such as blood transfusion, 
iron chelation and management of pain. Recently, a novel drug, 
Reblozyl (luspatercept-aamt) that modulates TGFβ-like path-
ways and improves RBC synthesis as well transfusion regimen, 
and has been approved for the treatment of β-thalassemia and 
MDS. BM transplantation has also been utilized as a definitive, 
although not without risk, curative option. Additional anemias 
are due to dietary limitation, such as folate, vitamin B12, and ID, 
while others are due to infections or exposure to toxic agents.
Plans for the future
Advances have been made in our understanding of mole-
cules and pathways that could be targeted to improve anemia. 
B-cell-CLL/lymphoma-11A (BCL11A) modulates the produc-
tion of fetal hemoglobin (HbF), is an important modifier of 
clinical severity in β-globinopathies.7 Furthermore, small mol-
ecule inhibitors inducing HbF, such as epigenetic enzymatic 
inhibitors, or directly inducing HbF or targeting transcription 
factors, are currently being evaluated for their therapeutic effi-
cacy.8 Molecules that control dietary iron absorption in the gut 
and hepcidin production in the liver, such as ferroportin (FPN), 
transferrin, erythroferrone (ERFE) and type-two transmem-
brane-serine-protease (TMPRSS6) have also been investigated 
for their contribution to iron overload and anemia in β-thalas-
semia.9 Gene therapy either via gene addition of β-globin10 or 
γ-globin gene11 and gene editing approaches have been intro-
duced as realistic alternatives to treat β-globinopathies.
Drugs that limit iron absorption and improve anemia 
are showing very promising results in preclinical studies.12 
Additional drugs that target oxidative stress (like peroxire-
doxin-2 agonists) and erythroid cell metabolism (like Glycine 
Transporter Type I Inhibitor or Pyruvate kinase agonists) are 
being investigated. Preclinical studies indicate that combinato-
rial therapies could further improve anemia.13 Gene therapy and 
gene editing trials for the cure of β-thalassemia and SCD show 
very promising results.7 These approaches are now waiting for 
the development of nontoxic myeloablative regimens. Genetic 
variability will likely influence the efficacy of these new thera-
peutics or therapies. For this reason, we recommend:
• The use of next-generation (-omics technologies) to assess 
the role of genetic makeup of the patients, modifiers, and 
environment, leading to personalized treatment for each 
individual affected by hereditary anemias.14
• To invest in these new lines of investigations and technol-
ogies to validate their potential, and transform them into 
effective and safe ways of treatment (Figure 1).
Efforts to develop new scientific discoveries and therapeutics 
can have a major impact, at multiple levels on the growing and 
aging population in Europe. Moreover, many additional incur-
able disorders could benefit from the development of gene ther-
apy and gene editing technologies designed for β-thalassemia, 




Iron deficiency anemia (IDA) is the most common form of 
anemia worldwide. IDA (and ID without anemia, which is even 
more common) poses a major burden to the society: they may 
cause cognitive defects in children, increased morbidity and 
mortality in pregnancy, reduced physical performance in work-
ers, and are common comorbidities in the elderly. Etiology, pop-
ulations at risk, and algorithms for diagnosing absolute ID/IDA 
are overall well established. More recently, also whole blood 
donors are identified as being at risk to develop ID, especially 
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at fast donation rates.15 Major challenges are diagnosing ID in 
nonerythropoietic tissues (eg, heart, kidney, and lungs) and in 
the context of inflammation. It is well known that microorgan-
isms compete with the human host for iron. An emerging issue 
in the field is the role of microbiota. Studies in mouse models 
suggest that gut microbiota might modulate iron absorption, 
counteracting the positive effect of duodenal HIF-2 alpha thus 
contributing to systemic iron homeostasis.16
Iron and iron proteins have a profound effect on erythro-
poiesis, and erythroid expressed ferroportin, exporting iron, 
protects red cells from oxidative stress and contributes to the 
levels of serum iron in ID.17 BM transferrin receptor 2 (TFR2) 
in complex with the erythroid receptor (EPOR) senses ID and 
modulates erythroid differentiation accordingly. Both genetic 
and acquired ID increase megakaryocyte commitment in mice,18 
providing a plausible explanation of thrombocytosis that can be 
observed in severe ID. In the therapeutic field, novel schedules 
of oral iron administration at alternate day suggest optimal effi-
cacy with less side effects, at least in ID19; indications to intra-
venous iron both in absolute and functional ID are increasing.20
Plans for the future
• It is urgent to clarify how ID affects tissues other than 
erythropoiesis in animal models.
• In particular, it is important to investigate how kidneys 
reabsorb iron and whether this participates to systemic 
homeostasis and to explore the contribution to iron bal-
ance of local hepcidin produced by different tissues. The 
value of soluble transferrin receptor, serum hepcidin lev-
els, and reticulocyte hemoglobin content should be bet-
ter explored in the diagnosis of complex cases of ID; the 
standardization of these parameters would further facili-
tate clinical use.
 • There is a need for identification and validation of func-
tional markers of ID beyond hemoglobin.
Future research should address:
• The physiological role of gut microbiome and its cross-
talk with the intestinal machinery of iron absorption. It is 
relevant to define whether and how gut microbiota mod-
ulate iron absorption, the role of microbiota in ID, its 
potential interference with pharmacological iron absorp-
tion and its role—if any—in the side effects caused by 
oral iron supplementation.
There is room for optimizing and personalizing ID treatment 
modalities:
• clear schedules should be established for oral iron treat-
ment in IDA, criteria for oral versus intravenous iron 
should be defined under different conditions and accord-
ing to disease severity;
• guidelines to replace total iron needs with single/double 
infusion(s) of intravenous iron should be drawn;
• iron supplementation strategies based on individual 
genetic susceptibility to ID should be considered;
• long-term complications of intravenous therapy not 
addressed in clinical trials should be explored;
Figure 1. Graphical representations of the aims of the Research Roadmap for Anemias in Europe during the period 2020–2025.
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• novel therapies for functional ID that counteract hepci-
din function or promote EPO production and iron mobi-
lization await clinical introduction.
Iron overload disorders
Where we are now
Disorders of systemic iron overload are a heterogeneous group 
of diseases classified into several subtypes based on the underly-
ing genetic or acquired cause. These include (1) primary genetic 
defects in proteins controlling iron homeostasis; (2) erythroid 
maturation defects resulting in secondary iron overload; and (3) 
very rare genetic conditions that include disorders of iron trans-
port, such as hypotransferrinemia, aceruloplasminemia, and 
DMT1 deficiency. Most frequently, misregulation of the hepci-
din-ferroportin regulatory axis is responsible for iron overload. 
In most subtypes of hemochromatosis, reduced hepcidin activity 
explains increased iron uptake mediated by the iron exporter 
ferroportin, while mutations in ferroportin hallmark ferroportin 
disease. In iron loading hematological diseases, including thal-
assemias, congenital hemolytic diseases, sideroblastic anemias, 
congenital dyserythropoietic anemias, myelodysplastic syn-
dromes, and aplastic anemia, inefficient erythropoiesis explains 
some degree of iron overload, which is severely aggravated by 
regular blood transfusions to treat anemia.
In the past 20 years, novel genes with critical roles in the 
generation of iron overload disorders were discovered and the 
subsequent development of experimental disease models had a 
tremendous impact on our understanding of the mechanisms 
that maintain cellular and systemic iron metabolism. Not only 
they explained the pathogenesis of hemochromatosis and other 
primary disorders of the hepcidin-ferroportin axis they also 
generated new insights into mechanisms underlying iron accu-
mulation in iron loading anemias. This knowledge enabled the 
development of novel treatment options for iron overload dis-
eases. Additionally, it laid the basis for research on the impact of 
iron in common acquired diseases, such as chronic liver disease, 
diabetes, neurodegeneration, atherosclerosis, or cardiovascular 
disease, where moderate elevations of tissue iron levels may 
exacerbate the underlying pathologies.
A major advance was the identification of erythroferrone 
(ERFE), a long-sought erythroid regulator of hepcidin synthe-
sis and iron homeostasis,21 and the recognition of its mecha-
nism of action.22 An ERFE immunoassay was developed for 
human studies of normal and disordered erythropoiesis and 
its effect on iron homeostasis.23 Mechanisms of iron-induced 
oxidative stress sensing in the liver were clarified with the 
demonstration that BMP6 production in sinusoidal endothe-
lial cells24 is under the control of the transcription factor NRF2 
in conditions of hepatic iron loading.25 Novel iron overload 
disease models revealed the importance of tissue-specific iron 
homeostasis and the impact of iron accumulation in different 
organs such as retina,26 lungs,27 heart,28 or the cardiovascu-
lar system.29 The role of TFR2 on the mutual control of iron 
homeostasis and erythropoiesis was revealed, opening a new 
door to potential novel therapeutic targets in iron-loading ane-
mias.30 This was also the era when novel targeted drugs such 
as hepcidin replacement therapy or hepcidin agonists were 
tested as novel approaches for treating iron overload under 
a variety of conditions, including iron-loading anemias.31 In 
addition, ferroportin inhibitors were first developed for thera-
peutic purposes.32 The role of the iron status of the mother on 
child’s health was assessed in a preclinical study showing that 
maternal hepcidin, through regulation of maternal plasma iron 
concentrations, determines the amount of iron taken up by the 
placenta and protects the fetus from iron excess even when the 
mother is iron overloaded.33
Plans for the future
We need basic research into mechanisms that maintain iron 
homeostasis under iron overload conditions and an increased 
demand for erythropoiesis. We further need to understand how 
iron accumulation in the BM affects early steps of hematopoie-
sis and the damage that occurs in diseases such as thalassemia, 
myelodysplasia, or leukemia.
• It is of interest to learn how specific organs handle iron or 
heme released during hemolysis, and the role of ferritin 
secretion on tissue iron redistribution.
• We need to investigate the role of the iron status of the 
mother on child’s health.
• Research is required to identify the role of proteins 
involved in iron regulation on different cell types, for 
example, of the immune system or in the brain.
• Definitely estimate the hemochromatosis prevalence 
in Europe, describe its natural history and clarify the 
genetic and environmental determinants of its pene-
trance. European registries promoted by EuroBloodNet 
are a critical requirement to fill this gap and for future 
implementation of preventive strategies.
• Epidemiological and prospective cohort studies are 
required to substantiate knowledge on how perturba-
tions of iron homeostasis are linked to disease progres-
sion and development of comorbid complications in 
acquired disorders, such as cancer, cardiovascular, liver, 
kidney, bone, or neurological diseases. This research may 
justify the implementation of clinical trials with the novel 
targeted therapies to reduce systemic iron levels.
• Research needs to support the initiative by the WHO to 
define adequate world-wide Hb values and its close link 
to iron availability.
Hemolytic anemias, including membrane and 
enzyme defects
Where we are now
Hemolytic anemias (HAs) are a heterogeneous group of 
hereditary and acquired disorders. The former includes defects 
of the red cell membrane and metabolism, and the latter warm 
autoimmune hemolytic anemia (wAIHA) and cold agglutinin 
disease (CAD). In the past 5 years, substantial improvement has 
been made with regard to dehydrated hereditary stomatocyto-
sis (DHS) or hereditary xerocytosis (HX), familial pseudohy-
perkalemia (FP), pyruvate kinase deficiency (PKD), CAD, and 
wAIHA.
Regarding DHS, during the last 5 years, the second caus-
ative locus, KCNN4 gene encodes for the Gardos channel, was 
identified.34–37 Senicapoc, a Gardos channel antagonist, previ-
ously proposed for use in sickle cell anemia, showed efficacy 
in preventing RBC K+ loss and dehydration in both PIEZO1 
and KCNN4 mutated cells.38–40 Moreover, two large retrospec-
tive cohort studies have been recently described comprising 
overall 249 patients with several forms of membrane defects 
due to altered transport function.41,42 These studies highlighted 
that PIEZO1 was the most frequent mutated gene under 
these conditions and that the major complication is the severe 
hepatic iron overload. A recent study demonstrated the role 
of PIEZO1 in the liver by regulation of hepcidin expression 
through increased phosphorylation of ERK1/2 and inhibition 
of the BMP-SMADs pathway. This was the first demonstration 
of a direct link between PIEZO1 and iron metabolism, which 
defines the channel as a new hepatic iron metabolism regulator 
and as a possible therapeutic target of iron overload in DHS 
and other iron-loading anemias.43 Furthermore, two recent 
studies have elucidated the role of PIEZO1 during erythroid 
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differentiation. PIEZO1 activation delays erythroid differenti-
ation of normal and DHS1-derived human progenitor cells.44 
Patients carrying PIEZO1 mutations showed reduced retic-
ulocyte count respect to patients with KCNN4 mutations, 
despite the similar Hb levels. Indeed, it has been demonstrated 
that PIEZO1 gain-of-function (GoF) mutations delay retic-
ulocyte maturation in DHS.45,46 PIEZO1 GoF mutations are 
also associated to resistance of Plasmodium infection in mice 
and human. As matter of fact, a novel human GoF PIEZO1 
allele, E756del, is present in a third of the African population 
(Figure 2).47
Regarding FP, it was demonstrated that the ABCB6 missense 
mutations cause elevated potassium ion efflux in RBCs.48 Of note, 
FP individuals are present in the blood donor population.48,49
Moreover, a genetic mutation in ATP11C, one of the major 
flippase of RBCs, was identified in a male affected by congeni-
tal hemolytic anemia inherited as an X-linked recessive trait.50
The widespread of NGS has revolutionized the field of diag-
nostic and research of new causative genes in these anemias. 
Indeed, the NGS targeted panels were routinely introduced in 
the diagnostic practice facilitating not only the diagnosis, but 
also the prognostic evaluation of these patients.51–53
Regarding PKD, recommendations for the diagnosis, includ-
ing pros and cons of enzymatic and molecular testing, have been 
published.54,55 Moreover, a large retrospective/prospective global 
registry of 254 patients has been activated, enabling a more pre-
cise definition of clinical and molecular features of the disease. 
In particular, treatments, complications, and their monitoring 
and management have been described.56,57 The most important 
therapeutic improvement regards mitapivat, a small molecule, 
an oral activator of red cell PK, which was administered in 52 
nontransfused patients with PKD, obtaining a maximal hemo-
globin increase >1 g/dL in half of the patients (median 3.5 g/dL), 
with an acceptable safety profile.58
Regarding CAD, a large retrospective multicenter study 
including 232 patients has better defined the clinical character-
istics and response to the few available treatments (rituximab 
alone or in combination with bendamustine or fludarabine).59,60 
Consistently, a pivotal study with the complement inhibitor 
sutimlimab (a humanized anti-C1s monoclonal antibody) has 
shown a mean hemoglobin increase of 2.6 g/dL, with 20/24 
(83.3%) patients displaying hemoglobin increase ≥1 g/dL, along 
with a meaningful improvement of quality of life.61 Finally, sev-
eral experts’ opinions and an International Consensus meeting 
have provided recommendations for the diagnosis and treat-
ment of wAIHA and CAD (Figure 3).62,63
Plans for the future
In the next years, regarding the RBCs membrane defects it 
will be important:
• to further understand the pathogenic mechanism of ane-
mia in DHS also by the use of the mouse model with 
PIEZO1 GoF mutations;
• the mechanism of hepatic iron overload in DHS needs 
further deeply dissection.
• to identify new causative genes for the cases still lacking 
a genetic base that are about 10%–15%.
• to find new therapeutic treatments.
The study of pathogenic mechanism will be useful for the 
identification and development of therapeutic treatments also in 
the field of gene therapy. Senicapoc seems to be a good promis-
ing drug to treat dehydration in DHS. A future clinical trial on 
the use of this drug in DHS could confirm its efficacy also in 
vivo. Regarding FP, could be useful to further dissect the role of 
ABCB6 and its correlation to blood transfusion.
• In the next years, ongoing long-term follow-up of mitapi-
vat-treated PKD patients will determine whether the rise 
in hemoglobin will also be associated with a decreased 
incidence of complications. Ongoing studies in transfu-
sion-dependent patients will confirm its efficacy in more 
severe settings (ClinicalTrials.gov NCT03559699).
• Following preclinical studies using a lentiviral vector 
in myeloablated PK-deficient mice, a clinical trial on 
gene therapy is close to start in humans (ClinicalTrials.
gov NCT04105166). This promising new therapeu-
tic approach will dramatically change the prognosis of 
severe PKD, unresponsive to splenectomy and mitapi-
vat, also considering the uncertain results with BM 
transplant.64
• Regarding wAIHA and CAD, several target therapies are 
under development, including inhibitors of complement 
(at different levels of the cascade), tyrosine kinases, protea-
some, and neonatal Fc-receptor (Figure 3) (ClinicalTrials.
gov NCT03538041, NCT03226678, NCT03075878, 
NCT04256148, NCT04119050, NCT02612558, 
NCT03764618, NCT04083014, NCT02389231).
In the next years, this expanded therapeutic armamentarium 
will help in defining the best choice, sequence and combination 
of drugs aimed at “cure” the disease.65
Congenital BM failure, aplastic anemias, PNH
Where we are now
BM failures (BMFs) are a heterogeneous group of diseases 
characterized by a quantitative deficiency in one or more 
blood cell lineages. Inherited BMFs are rare and include dif-
ferent entities such as Fanconi’s anemia (FA, which is due 
to impaired DNA repair and cytokine hypersensitivity),66 
Dyskeratosis Congenita (DKC), Diamond Blackfan Anemia 
(DBA), and Shwachman-Diamond Syndrome (SDS) (all 
associated with impaired ribosomal or telomere function). 
Acquired forms of BMF are more frequent; the most typi-
cal form is idiopathic aplastic anemia (IAA), characterized 
by a severe pancytopenia due to an immune-mediated attack 
of hematopoiesis. PNH is a less common form, where the 
underlying BM disorder is associated with the expansion of 
an abnormal, nonmalignant, blood cell population which is 
deficient in the expression of glycosyl-phosphatidyl-inositol 
(GPI)-linked proteins due to a somatic PIG-A mutation. Since 
lacking GPI-linked proteins include the complement regula-
tors CD55 and CD59, the clinical phenotype of PNH is char-
acterized by complement-mediated, intravascular, hemolytic 
anemia, variously embedded with thromboembolisms and 
cytopenia.
The improved understanding of all BMFs has led to better 
patient management in Europe; the Severe Aplastic Anemia 
Working Party (SAAWP) of the EBMT historically has con-
tributed greatly to improved clinical outcome in this field, pio-
neering the therapeutic use of antithymocyte globulin (ATG) 
in IAA, as well as the use of HSCT in patients with FA and 
other inherited forms. The database of the SAAWP of the 
EBMT contains data on >16,000 patients with different sub-
types of BMFs, thereby providing a unique opportunity for 
investigating many different critical aspects of these diseases. 
The SAAWP of the EBMT continues to run a multinational 
database to collect data from all European BMFs, aiming to 
perform robust retrospective studies. At the same time, the 
SAAWP is now fully equipped for academic prospective trials: 
the RACE study, the largest clinical trial performed in IAA, has 
just been completed.
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Plans for the future
Patients suffering from BMFs continue to represent a chal-
lenge for the medical community, for their poor prognosis when 
the underlying disease is not controlled. Additional efforts are 
needed to offer the most appropriate treatment to all European 
patients, and to improve current standards of care. The SAAWP 
of the EBMT is dedicated to this goal through different research 
lines.
Improvements in HSCT for inherited and acquired forms of 
BMF. HSCT remains a key treatment option for all BMF patients, 
with the actual indication depending on the phase/severity of 
the disease and on the availability of alternative treatments. The 
SAAWP is actively working to improve the outcome of HSCT in 
all these conditions, mostly through high-quality registry retro-
spective studies, implementing:
• Disease-specific, patient-tailored, conditioning regimen as 
well as post-HSCT immunosuppressive treatments;
• Development of novel HSCT protocols in the setting of 
alternative donor, including not only HSCT from unre-
lated donors, but also HSCT from familiar haploidentical 
donors;
• Demonstration of more effective treatment algorithm for 
individual forms of acquired or inherited BMFs.
• Improvement of nontransplant treatment for acquired 
IAA. After years of failures trying to develop more aggres-
sive immunosuppressive regimens, the treatment of IAA 
has been improved by the addition the thrombopoie-
tin-mimetic agent eltrombopag on the ‘scaffold’ of stan-
dard immunosuppression. After the initial results coming 
from the United States,67 the SAAWP has just announced 
the results of a pivotal randomized trial which has demon-
strated the superiority of horse antithymocyte globulin 
(ATG) + cyclosporine (CsA) +Eltrombopag (the “triple 
therapy”) as compared with standard horse-ATG+CsA.
• Improvement of management of PNH. The introduction 
of the anti-complement agent eculizumab led to the con-
trol of most disease manifestations and to improved sur-
vival in PNH. The SAAWP is currently looking at unmet 
clinical needs in PNH, as well as to improve the mech-
anistic understanding of anticomplement treatment in 
vivo, paving the way for the development of more effec-
tive treatments.68 Pivotal clinical trials are ongoing, and 
preliminary data already anticipate the a novel scenario 
in the field of anticomplement treatment for PNH.
The management of BMFs still represents a challenge for the 
medical community. European efforts aiming to investigate in 
the real-life the actual impact of these disorders is essential to 
improve the management of all BMFs. Considering the rarity of 
these conditions, as well as the growing cost of available ther-
apies, these research studies are essential not only to develop 
better treatments, but also to optimize the financial resources.
Thalassemia and congenital 
hemoglobinopathies
Where we are now
A better understanding of the pathophysiology of β-thal-
assemia in addition to key developments in optimizing trans-
fusion programs and iron-chelation therapy has led to an 
Figure 2. Schematic representation of pathogenic mechanism of DHS and new discovery on Plasmodium infection. (A) Recent study demonstrated 
that RBCs of DHS patients with PIEZO1 gain-of-function (GOF) mutations show a low rate of infection by Plasmodium falciparum. (B) RBCs of DHS patients 
show dehydration that is caused by the increased potassium efflux and increased calcium influx of PIEZO1 GoF mutations or KCNN4/Gardos GoF mutations. 
Senicapoc, a Gardos antagonist, is able to restore the hydration status in both PIEZO1 and KCNN4 mutants. (C) RBCs of DHS patients with GoF mutations in 
PIEZO1 show delayed terminal differentiation and reticulocytes maturation. (D) At the hepatic level, PIEZO1 GoF mutations in DHS result in increased intracellular 
Ca2+ concentrations. The hyperactivation of the mechanoreceptor leads to amplification of the phosphorylation of ERK1/2, which acts in turn by inhibiting the 
BMP/SMADs pathway. The lack of phosphorylation of SMAD1/5/8 inactivates HAMP transcription.
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increase in the life span of thalassemia patients and paved the 
way for novel therapeutic strategies.69,70 The latest advance-
ment and breakthrough in the thalassemia realm during the 
past years is the FDA and EMA approval of luspatercept for 
the treatment of transfusion-dependent thalassemia (TDT) 
patients at a starting dose of 1 mg/kg once every 3 weeks by 
subcutaneous injection. Luspatercept or ACE-536 is a recom-
binant fusion protein that acts as a trap for activin receptors. 
The approval was based on the results of the BELIEVE trial, 
a phase 3, randomized, double-blind, placebo-controlled trial 
that was conducted in 65 sites across 15 countries, enroll-
ing a total of 336 adult TDT patients (>18 years) randomized 
in a 2:1 ratio to receive luspatercept or placebo subcutane-
ously every 21 days for at least 48 weeks.71 The percentage of 
patients who had a reduction in the transfusion burden of at 
least 33% from baseline during weeks 13 through 24 plus a 
reduction of at least 2 red-cell units over this 12-week inter-
val was significantly greater in the luspatercept group than in 
the placebo group (21.4% versus 4.5%, P < 0.001).71 During 
any 12-week interval, the percentage of patients who had a 
reduction in transfusion burden of at least 33% was greater 
in the luspatercept group than in the placebo group (70.5% 
versus 29.5%). Similarly, the percentage of those who had a 
reduction of at least 50% was also greater in the luspater-
cept group, compared to placebo (40.2% versus 6.3%). AEs 
included bone pain, arthralgia, dizziness, hypertension, and 
hyperuricemia. These were more commonly seen in patients 
on luspatercept than those on placebo. A greater percentage of 
patients in the luspatercept group than in the placebo group 
had at least one AE of grade 3 or higher during the treat-
ment period. Treatment discontinuation due to an AE was 
reported in 12 patients (5.4%) in the luspatercept group and 
in 1 patient (0.9%) in the placebo group. No deaths related to 
luspatercept or placebo were reported.71
Plans for the future
Ongoing clinical trials are currently underway looking at the 
use of luspatercept in different settings:
• A phase 2a study is currently ongoing to evaluate the 
safety and pharmacokinetics of luspatercept in pedi-
atric patients with TDT (ClinicalTrials.gov number 
NCT04143724).
• The BEYOND trial is another ongoing phase 2 trial look-
ing at the efficacy and safety of luspatercept in patients 
Figure 3. Standard and target therapies for warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease (CAD). The figure shows the 
several immunologic mechanisms involved in pathogenesis, including macrophages, T and B lymphocytes, cytokines, activation of the complement cascade, 
antibody-dependent cellular cytotoxicity (ADCC) in the spleen and/or complement-dependent cytotoxicity (CDC) in the liver, and possible inadequate bone 
marrow compensation. Standard therapies include steroids and immunosuppressors that act not specifically on the various mechanisms, and splenectomy. 
Target therapies are directed against specific immunological mechanisms either inhibiting the immune attack or stimulating bone marrow compensation. APC = 
antigen presenting cell; BAFF = B-cell activating factor; BM = bone marrow; BTK = Bruton tyrosine kinase; CAD = cold agglutinin disease; EPO = erythropoietin; FcRn = neonatal Fc receptor; 
MMF = mycophenolate mofetil; PI3K = phosphoinositide 3-kinase; Syk = spleen tyrosine kinase.
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with nontransfusion-dependent thalassemia (NTDT) 
(ClinicalTrials.gov number NCT03342404).
• Several other clinical trials are investigating the safety and 
efficacy of gene therapy and genome editing to restore Hb 
synthesis in β-thalassemia.
• Clinical trials investigating the use of novel therapeutic 
agents targeting iron dysregulation are also currently 
underway and details of these trials have been sum-
marized in recent publications. These agents stimulate 
hepcidin expression and activity and/or target the hep-
cidin-ferroportin axis and include minihepcidins, ferro-
portin inhibitors, and TMPRSS6 inhibitors. They have 
already been investigated in preclinical studies on animal 
models, demonstrating a beneficial activity.32,72–74 Several 
other agents are in evaluation for a similar effect in these 
patients. These agents directly target iron dysregulation 
(VIT-2763 and TMPRSS6- LRx)32,75 or ineffective eryth-
ropoiesis (mitapivat [AG-348]) to ameliorate anemia 
and prevent iron overload, which are strictly related. 
Combinations of these agents may be useful to control or 
reverse the disease process in β-thalassemia.76
As we await the data from all these trials, we believe that 
long-term, head-to-head, and comparison trials using these 
novel therapies will be necessary in the future to determine their 
optimal use. Moreover, whether these novel therapies will be 
used on their own or in combination with other conventional 
therapies, such as iron chelators are yet to be determined.
Sickle cell disease
Where we are now
SCD is the commonest severe monogenic disease in the world.77 
It is caused by a point mutation in the β-globin gene, resulting in 
the synthesis of pathological hemoglobin S (HbS). The term SCD 
includes different genotypes that cause the characteristic clinical 
syndrome (SS, SC, Sβ+/0 thalassemia). SCD causes chronic mor-
bidity and high mortality related to the severity of both acute and 
chronic organ damage. In the last 2 decades, due to immigration, 
the number of patients with SCD has dramatically increased 
across Europe. The prevalence of SCD newborns and SCD car-
riers in EU is approximately 1–5/10,000 and 1/150, respectively, 
and is set to increase in the near future. The years lived with dis-
ability (YLDs) for hemoglobinopathies and SCD is estimated to 
be 10,197, which is a very significant, considering that the YLDs 
for cardiovascular disorders is 21,985. In high-income countries, 
nearly all children with SCD are expected to survive to adulthood, 
although mortality increases in adulthood and median survival is 
reduced by >20 years.78 In low-income countries, the majority of 
patients with SCD still die in childhood. SCD was first described 
by James Herrick in 1910, and understanding has increased 
steadily since then, including recognition that polymerization of 
deoxygenated HbS is the primary event, and that a cascade of 
pathological problems, including: red cell dehydration, vaso-oc-
clusion, hemolysis, anemia, inflammation, hypercoagulability, and 
aberrant expression of adhesion molecules.79,80 Past achievements 
in Europe include defining the structure of HbS polymers, identifi-
cation of embryonic hemoglobins, evaluation of hydroxyurea, the 
development of comprehensive sickle cell centers, the development 
of HSCT, and the first clinical trials of gene therapy in SCD.81,82 In 
addition, European research contributed to the development of 
the first transgenic mouse model for SCD-related organ damage, 
and understanding of the control of HbF expression.
Plans for the future
Although significant progress has been made in the clinical 
management of patients with SCD, the treatment of SCD is still 
unsatisfactory, with few effective treatments. More therapeutic 
approaches are starting to emerge as gene therapy. There are 
ongoing clinical trials assessing the efficacy and safety of gene 
therapy in SCD patients, but the results are not yet available. 
The ongoing clinical trials are assessing the efficacy in different 
types of SCD based on the types of mutations and types of vec-
tors available. Moreover, genome editing technology has made 
it possible to repair the β-globin mutation in patient HSCs or 
target genetic loci associated with reactivation of endogenous 
γ-globin expression.83
The roadmap for research on SCD in Europe includes:
• the development of multinational collaborative studies 
across Europe to establish biobanks to identify genetic 
and other biomarkers predicting outcomes in SCD, which 
will be useful in clinical care and therapeutic trials. This 
will include collection of detailed phenotypes;
• selection of new therapeutic targets using both in vitro 
and animal models for SCD;
• development of novel imaging techniques for both clinical 
and research purposes;
• establishment of network of SCD clinical trials units to 
assess and develop the new treatments, including stem 
cell therapies, small molecules and supportive care. In 
addition, the recent COVID-19 pandemic has highlighted 
the importance of EU action to support and intensively 
treat fragile patients such as SCD subjects.84
The proposed research roadmap will help develop:
• progress in the knowledge of disease progression;
• new therapeutic molecules for management of SCD;
• new profiling of disease severity for personalized medicine;
• optimization of SCD patient care;
• clinical trials addressing basic aspects of clinical cares.
These will improve:
• patient health and quality of life;
• national and European Health systems by reductions of 
hospitalization length and of care costs;
• national and European Welfare spending due to the 
reduction in disabilities of SCD patients and in the level 
of sickness absence from jobs.
These advances would benefit patients in the United States, 
and low- and middle-income countries, including many African 
countries, India, and Brazil. This research will also stimulate col-
laboration with commercial companies.
Dyserythropoietic and hyporegenerative 
anemias
Where we are now
Dyserythropoietic and hyporegenerative anemias comprise a 
heterogeneous group of disorders that affect the normal differ-
entiation–proliferation pathways at the different steps through 
the erythroid lineage, and that mainly result in monolinear 
cytopenia.85
The congenital dyserythropoietic anemias (CDAs) are a 
group of disorders characterized by anemia caused by ineffec-
tive erythropoiesis, erythroid hyperplasia with distinct morpho-
logical features in BM late erythroblasts, and often associated 
with secondary iron overload. Based on BM morphology, the 
CDAs are classically divided into 3 types (CDA I, II, and III), 
a classification that is now supported by the identification of 
different genes mutated in each type.86 Mutations in eryth-
roid-specific transcription factors genes GATA1 and KLF1 (des-
ignated CDA type IV) have been described in few such patients. 
Dyserythropoietic changes were described in several disorders 
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with additional clinical features like sideroblastic anemia, 
Majeed syndrome (LPIN2 mutations), epileptic encephalopa-
thy (CAD), pancreatic insufficiency (COX4I2), and mevalonate 
kinase deficiency (MVK) and thus add to diagnostic confusion.87
It has been shown recently that the nonspecific clinical pic-
ture and light microscopy BM findings cause diagnostic diffi-
culties with delay diagnosis and appropriate therapy. Indeed, 
a genetic-based NGS diagnostic led to modification of original 
clinical diagnosis in 10%–40% of patients.51,52,88 For example, a 
recent case series showed that among patients originally classi-
fied with CDAs, 45% had anemia caused by enzymatic defects, 
most commonly pyruvate kinase deficiency with mutations in 
the PKLR gene.52
Regarding the pathogenesis of the CDAs, proteins encoded 
by involved genes are ubiquitous expressed and their role in 
erythropoiesis is still unknown. CDA I is caused by mutations in 
CDAN1 or in CDIN1 (previously known as C15orf41) genes. 
It has been recently found that the protein encodes by CDAN1 
tightly binds to C15orf41 and sequester C15orf41 and Asf1 in 
the cytoplasm pointing to involvement in chromatin assembly 
processes.89,90 CDA II is the most common CDA subtype and 
results from mutations in SEC23B (>80% of cases). Recently, 
a recurrent low-frequency variant in the ERFE gene, encoding 
the erythroferrone, was identified in 12.5% of CDA II patients 
with severe phenotypes. This variant results in increased levels 
of ERFE, with subsequent marked impairment of iron regula-
tion pathways at the hepatic level.91
Diamond Blackfan anemia (DBA) patients classically show 
severe macrocytic anemia in the first year of life. The BM is char-
acterized by a paucity of erythroid precursors. Approximately, 
30% of DBA patients also have physical anomalies (eg, cranio-
facial, thumb, and cardiac malformations). The risk of solid 
tumors, myelodysplastic syndrome, or leukemia is elevated in 
DBA and was calculated to be 20% by age 46 years.92 Following 
the first year of life, the anemia is treated with corticosteroids. 
Patients who do not respond to steroids or require high doses 
with unacceptable toxicities or infants in the first year of life 
receive chronic RBC transfusions.93 Those patients often develop 
substantial iron overload and require careful detection of iron 
overload, as well as, iron chelation therapy.
Stem cell transplantation is an alternative to chronic transfu-
sions. Excellent results of stem cell transplantation have recently 
been observed (91% overall survival) in young children with 
DBA using matched sibling donors and matched unrelated 
donors.94
DBA is caused by mutations in least 20 genes encoding ribo-
somal proteins (RPs) resulting in ribosomal haploinsufficiency. 
Mutations in ribosomal genes account for 60%–70% of DBA 
cases. “DBA-like” disorders with congenital red cell aplasia and 
intact ribosomal function were described, including biallelic 
pathogenic mutations in CECR1 gene coding for adenosine 
deaminase 2 (ADA2) and in the erythropoietin (EPO) gene.95,96
Regarding the pathogenesis of DBA, the effect of decreased 
ribosomal activity in vivo and in a tissue-specific manner is 
unknown; p53 activation has been observed in BM from DBA 
patients, after depletion of RPs. Recently, it has been shown 
that rarely mutations in the GATA1 gene can cause DBA. 
Subsequently, an elegant study suggested that impaired trans-
lation of GATA1 mRNA (as a consequence of RP haploinsuffi-
ciency) is an important factor in mediating the erythroid defect 
observed in DBA. It has further been suggested that GATA1 has 
a complex 5′ UTR that predicts poor translation initiation rates, 
and such mRNAs are more sensitive to ribosome deficiency as 
found in DBA.97 Two recent articles suggested that a decrease of 
GATA1 full-length protein resulting from RP haploinsufficiency 
and deficiency of HSP70 can disturb the balance of globin-heme 
and lead to the accumulation of free cytoplasmic heme in eryth-
roid progenitors, which increase the P53-dependent apoptosis 
of DBA erythroid cells.98 An alternative model suggests that 
both RP and GATA1 mutant cells showed reduced proliferation 
and delayed erythroid differentiation.
Plans for the future
There is a need for wide implementation of NGS programs to 
improve diagnosis, for more basic research to better understand 
the role of the proteins involved normal and affected erythro-
poiesis, and for programs to identify new potential drugs and 
therapeutic options for patients with these rare disorders.
• Improving CDA and DBA European Registries by harmo-
nization and collaboration among the existing national 
registries to create a unique European database.
• Continued wide implementation of NGS molecular diag-
nosis to achieve a correct diagnosis and to further identify 
new candidate genes.
• Continued efforts for unraveling the pathogenesis of both 
disorders and the role of the involved proteins in eryth-
ropoiesis which eventually may lead to discovery of new 
therapeutic targets. The existence of appropriate eryth-
roid models like induced pluripotent stem cell (iPSC cells) 
and human erythroblasts cell lines capable of terminal 
erythroid maturation may facilitate this effort.
• Clinical trials of novel drugs: Results of clinical trial 
of L-leucine in DBA are awaited (ClinicalTrials.gov 
NCT01362595). TGF-β ligand modifiers correct anemia 
by promoting the late-stage erythropoiesis. Sotatercept 
was administered to DBA patients (ClinicalTrials.
gov NCT01464164) and results are still pending, and 
Luspatercept was recently approved (by Celgene) for 
CDA II patients.
• Gene therapy and gene editing for patients with DBA is 
an attractive potential therapy. The feasibility of gene 
therapy to cure RPS19-deficient DBA mouse model 
using lentivirus vectors have been shown.99 Future stud-
ies in transduced human CD34 cells and clinical trials 
are awaited. The fast-moving CRISPR/Cas9-mediated 
genome editing may offer BM cure without the use of an 
integrating viral vector.
Anemia in the elderly
Where we are now
The recent years have witnessed an increased awareness on the 
huge prevalence of anemia in the elderly (AE), and its negative 
prognostic impact.100,101 In 2018, nearly on fifth of the EU popu-
lation (estimated at 512 million) was aged >65 years, with pro-
jections towards a continuously increasing proportion, especially 
for the “oldest old” (ie, those aged >85 years; https://ec.europa.
eu/eurostat/statisticsexplained/index.php/Population_struc-
ture_and_ageing#Past_and_future_population_ageing_trends_
in_the_EU). Anemia reveals a prevalence ranging from 12% 
in community living up to 47% in nursing home residents.102 
Remarkably AE is independently associated with impaired 
patient-reported outcomes,103 and a number of adverse outcomes 
including hospitalizations, frailty, and even mortality. Thus, AE 
clearly represents a forthcoming EU major public health problem. 
Traditionally, AE has been attributed by one third to nutritional 
deficiency (primarily ID), one-third to chronic inflammation 
(AI) and/or other comorbidities (eg, CKD),104 while the remain-
ing third has been considered “unexplained.” However, recent 
advances suggest that: (1) at variance with anemia in younger 
persons where a single cause is the rule, AE is near invariably 
multifactorial100,101; (ii) absolute ID is underrecognized in the 
elderly, due to the frequent absence of microcytosis,101 as well 
as the unawareness of the need of considering upper ferritin 
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thresholds than those commonly used in the young105; (iii) hep-
cidin upregulation leading to functional ID is relatively common 
in elderly, due not only to comorbidities (including CKD and 
chronic heart failure [CHF]),106 but also to reduced levels of sex-
ual hormones and to a low-grade inflammatory process linked to 
age and immunosenescence termed “inflammaging”107; indeed, 
patients with AI reveal pronounced restrictions in health-related 
quality of life (HRQoL) as compared with other forms of ane-
mia; and (4) besides unrecognized ID, a proportion of “unex-
plained” AE is associated to age-related clonal hematopoiesis of 
indeterminate potential,108 a process driven by acquired somatic 
mutations in certain genes (eg, TET2, DNMT3A, and JAK2) also 
predisposing to myelodysplastic syndromes (MDS) and other 
hematological malignancies. When CHIP is associated to iso-
lated anemia without fulfillment of other MDS diagnostic crite-
ria, the condition is named “isolated cytopenia of undetermined 
significance (ICUS) with anemia (ICUS-A), regarded as a possible 
prototype of “unexplained” AE.100 Noteworthy, CHIP has been 
consistently associated with increased mortality due to cardio-
vascular rather than hematological complications, likely through 
a CHIP-induced proinflammatory state.109
In summary, it is clear that AE, even mild, can no longer be 
considered as a mere consequence of aging, but should be always 
taken seriously. A precise definition of the cause(s) in the indi-
vidual patient, which is instrumental to anemia correction, is far 
from easy and can be demanding for either patients or physicians.
Plan for the future
Despite the remarkable progress outlined above, a number of 
critical issues should be addressed in the coming years:
• Hb thresholds for AE are still incompletely defined, espe-
cially in the oldest old. Studies enrolling adequate number of 
elderlies without significant comorbidities (“wellderly” sub-
jects)110 may be the key for resolving this long-debated issue.
• Specific guidelines or recommendations on AE diagnosis 
and management are scarcely available. Multidisciplinary 
efforts in this sense should be promoted, for example, 
regarding the appropriateness and cost-effectiveness of 
searching intensively the cause, particularly in vulnerable 
and frail patients.
• Nutritional AE is in principle effectively correctable with 
relative safe and inexpensive supplementations, but needs 
an accurate diagnosis. Future studies should clarify the 
appropriate cutoff levels of old and new laboratory tests, 
not only for ID,20 but also for B12 and folate deficiency.
• The independent association of AE with major adverse 
outcomes including mortality is highly suggestive but 
does not represent a definite proof of causality of ane-
mia per se, or of a distinct additive effect beyond that 
of comorbidities. Such proofs may derive by showing 
improved outcomes with anemia correction. Encouraging 
results already established for some specific conditions 
very common in the elderly (eg, CHF)106 cannot be gen-
eralized to all AE. Nonetheless, with the increasing avail-
ability of novel antianemic drugs,111 future studies in this 
sense should be promoted.
• Patient-reported outcomes including HRQoL with focus 
on physical functioning and fatigue should be included in 
initial assessment and evaluation of treatment response.
• So far, only a few studies have addressed the relative 
contribution of CHIP to AE.112,113 This should be further 
investigated, as well as the reciprocal influences between 
CHIP and inflammaging, which can elicit a detrimental 
loop.114 This would be of particular interest considering 
the results of a recent proof-of-concept analysis on the 
beneficial effects of anticytokine agents on AE.115
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